Results of the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) study undertaken by the National Cancer Institute identified new gene mutations, including CRLF2, IL-7R, JAK1, and JAK2, which assign ALL patients to a high-risk group [71]. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.